Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients

C. Viscoli, M. Paesmans, E. Castagnola, J. Klastersky, P. Martino, M. Glauser

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated wtih bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.

Original languageEnglish
Pages (from-to)1532-1537
Number of pages6
JournalClinical Infectious Diseases
Volume32
Issue number11
DOIs
Publication statusPublished - Jun 1 2001

Fingerprint

Bacteremia
Antifungal Agents
Fever
Febrile Neutropenia
Neoplasms
Confidence Intervals
Neutropenia
Granulocytes
Shock
Hospitalization
Catheters
Odds Ratio
Temperature

ASJC Scopus subject areas

  • Immunology

Cite this

Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. / Viscoli, C.; Paesmans, M.; Castagnola, E.; Klastersky, J.; Martino, P.; Glauser, M.

In: Clinical Infectious Diseases, Vol. 32, No. 11, 01.06.2001, p. 1532-1537.

Research output: Contribution to journalArticle

@article{7e260195c25848d3a4c5b847c30d0ab5,
title = "Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients",
abstract = "Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44{\%}) did not receive antifungal prophylaxis; 835 (28{\%}) received poorly absorbable antifungal agents and 845 (28{\%}) received absorbable antifungal agents. The rates of bacteremia for these groups were 20{\%}, 26{\%}, and 27{\%}, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated wtih bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95{\%} confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95{\%} CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.",
author = "C. Viscoli and M. Paesmans and E. Castagnola and J. Klastersky and P. Martino and M. Glauser",
year = "2001",
month = "6",
day = "1",
doi = "10.1086/320514",
language = "English",
volume = "32",
pages = "1532--1537",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "NLM (Medline)",
number = "11",

}

TY - JOUR

T1 - Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients

AU - Viscoli, C.

AU - Paesmans, M.

AU - Castagnola, E.

AU - Klastersky, J.

AU - Martino, P.

AU - Glauser, M.

PY - 2001/6/1

Y1 - 2001/6/1

N2 - Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated wtih bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.

AB - Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated wtih bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92-1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07-1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.

UR - http://www.scopus.com/inward/record.url?scp=0035370167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035370167&partnerID=8YFLogxK

U2 - 10.1086/320514

DO - 10.1086/320514

M3 - Article

VL - 32

SP - 1532

EP - 1537

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -